[{"address1": "Bahnhofstrasse 7", "city": "Zug", "zip": "6300", "country": "Switzerland", "phone": "41 41 711 9325", "website": "https://oculis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Dr. Riad  Sherif M.B.A., M.D.", "age": 56, "title": "CEO & Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sylvia  Cheung", "age": 49, "title": "Chief Financial Officer", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gudrun  Bachmann Ph.D.", "title": "Chief Technology Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ramin  Tadayoni M.D., Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel S. Char J.D.", "age": 63, "title": "Chief Legal Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Virginia R. Dean", "age": 57, "title": "Chief Human Resources Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. P\u00e1ll Ragnar J\u00f3hannesson", "age": 42, "title": "Chief Business Officer", "yearBorn": 1982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rebecca  Weil", "title": "Chief Commercial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Snehal  Shah Pharm.D.", "title": "President of Research & Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Klier M.D., M.P.H.", "title": "Chief Development Officer", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 19.4, "open": 19.45, "dayLow": 19.06, "dayHigh": 19.89, "regularMarketPreviousClose": 19.4, "regularMarketOpen": 19.45, "regularMarketDayLow": 19.06, "regularMarketDayHigh": 19.89, "payoutRatio": 0.0, "beta": 0.051, "forwardPE": -8.5625, "volume": 35668, "regularMarketVolume": 35668, "averageVolume": 74985, "averageVolume10days": 36180, "averageDailyVolume10Day": 36180, "bid": 14.04, "ask": 24.65, "bidSize": 1, "askSize": 2, "marketCap": 920640000, "fiftyTwoWeekLow": 10.55, "fiftyTwoWeekHigh": 23.08, "priceToSalesTrailing12Months": 1342.0408, "fiftyDayAverage": 20.6694, "twoHundredDayAverage": 15.62663, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 917977152, "profitMargins": 0.0, "floatShares": 44408117, "sharesOutstanding": 48000000, "sharesShort": 34714, "sharesShortPriorMonth": 29073, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0007, "heldPercentInsiders": 0.07039, "heldPercentInstitutions": 0.3104, "shortRatio": 0.69, "shortPercentOfFloat": 0.00090000004, "impliedSharesOutstanding": 49362400, "bookValue": 1.681, "priceToBook": 11.409875, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -85777000, "trailingEps": -2.4, "forwardEps": -2.24, "enterpriseToRevenue": 1338.159, "enterpriseToEbitda": -12.61, "52WeekChange": 0.65060246, "SandP52WeekChange": 0.06429911, "quoteType": "EQUITY", "currentPrice": 19.18, "targetHighPrice": 41.129898, "targetLowPrice": 22.112785, "targetMeanPrice": 32.078182, "targetMedianPrice": 32.100746, "recommendationKey": "none", "numberOfAnalystOpinions": 7, "totalCash": 98663000, "totalCashPerShare": 1.864, "ebitda": -72798000, "totalDebt": 1180000, "quickRatio": 2.248, "currentRatio": 2.371, "totalRevenue": 686000, "debtToEquity": 1.608, "revenuePerShare": 0.017, "returnOnAssets": -0.38987, "returnOnEquity": -1.02659, "grossProfits": -51397000, "freeCashflow": -8057875, "operatingCashflow": -47499000, "revenueGrowth": -0.984, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -5753.333, "financialCurrency": "CHF", "symbol": "OCS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "postMarketTime": 1743192312, "regularMarketTime": 1743192000, "exchange": "NGM", "messageBoardId": "finmb_589165623", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "Oculis Holding AG", "shortName": "Oculis Holding AG", "regularMarketChangePercent": -1.1340171, "regularMarketPrice": 19.18, "regularMarketChange": -0.21999931, "regularMarketDayRange": "19.06 - 19.89", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 74985, "fiftyTwoWeekLowChange": 8.63, "fiftyTwoWeekLowChangePercent": 0.8180095, "fiftyTwoWeekRange": "10.55 - 23.08", "fiftyTwoWeekHighChange": -3.8999996, "fiftyTwoWeekHighChangePercent": -0.16897745, "fiftyTwoWeekChangePercent": 65.06025, "earningsTimestamp": 1741770000, "earningsTimestampStart": 1741770000, "earningsTimestampEnd": 1741770000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.4, "epsForward": -2.24, "epsCurrentYear": -1.69951, "priceEpsCurrentYear": -11.285606, "fiftyDayAverageChange": -1.489399, "fiftyDayAverageChangePercent": -0.07205816, "twoHundredDayAverageChange": 3.5533705, "twoHundredDayAverageChangePercent": 0.22739199, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2023-03-03", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1621344600000, "postMarketChangePercent": 0.0, "postMarketPrice": 19.18, "postMarketChange": 0.0, "corporateActions": [], "trailingPegRatio": null, "__fetch_time": "2025-03-29"}]